These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 8301879)
1. Concentration of neural thread protein in cerebrospinal fluid from progressive supranuclear palsy and Parkinson's disease. Yamada T; Chong JK; Asahina M; Koguchi Y; Hirayama K Jpn J Psychiatry Neurol; 1993 Sep; 47(3):631-5. PubMed ID: 8301879 [TBL] [Abstract][Full Text] [Related]
2. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Holmberg B; Rosengren L; Karlsson JE; Johnels B Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329 [TBL] [Abstract][Full Text] [Related]
3. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882 [TBL] [Abstract][Full Text] [Related]
4. Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. Schirinzi T; Sancesario GM; Di Lazzaro G; Scalise S; Colona VL; Imbriani P; Mercuri NB; Bernardini S; Lang AE; Pisani A J Neural Transm (Vienna); 2018 Sep; 125(9):1373-1379. PubMed ID: 29948175 [TBL] [Abstract][Full Text] [Related]
5. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779 [TBL] [Abstract][Full Text] [Related]
6. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis. Sako W; Murakami N; Izumi Y; Kaji R Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345 [TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid levels of oxidative stress measured using diacron-reactive oxygen metabolites and biological antioxidant potential in patients with Parkinson's disease and progressive supranuclear palsy. Takahashi K; Iwaoka K; Takahashi K; Suzuki Y; Taguchi K; Yamahara K; Maeda T Neurosci Lett; 2021 Jul; 757():135975. PubMed ID: 34023404 [TBL] [Abstract][Full Text] [Related]
8. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Borroni B; Malinverno M; Gardoni F; Alberici A; Parnetti L; Premi E; Bonuccelli U; Grassi M; Perani D; Calabresi P; Di Luca M; Padovani A Neurology; 2008 Nov; 71(22):1796-803. PubMed ID: 18971445 [TBL] [Abstract][Full Text] [Related]
9. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis. Sako W; Murakami N; Izumi Y; Kaji R J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897 [TBL] [Abstract][Full Text] [Related]
10. CSF α-synuclein as a diagnostic biomarker for Parkinson disease and related dementias. Ballard CG; Jones EL Neurology; 2010 Nov; 75(20):1760-1. PubMed ID: 20962288 [No Abstract] [Full Text] [Related]
11. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Holmberg B; Johnels B; Blennow K; Rosengren L Mov Disord; 2003 Feb; 18(2):186-90. PubMed ID: 12539213 [TBL] [Abstract][Full Text] [Related]